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To date, targeted temperature management (TTM) is
the only neuroprotective intervention after resuscitation
from cardiac arrest that is recommended by guidelines.
When studied in animals, interventions to lower the body
temperature during cardiopulmonary arrest (intra-ische-
mic cooling) appear to attenuate brain damage and
improve survival.1,2 Cooling induced after the cardiac
arrest (post-ischemic cooling) with a delayed onset might
also be beneficial.3,4 In dogs, delayed post-ischemic
cooling was less effective than immediate hypothermia
after defibrillation.5
In humans, post-arrest hypothermia has shown favor-
able results in one randomized trial and one quasi-
randomized trial. These two trials reported improved
neurological outcome at 6 months6,7 and one suggested
improved survival.6 Outcomes from two smaller random-
ized trials have also been published.8,9
In total, less than 500 participants have been included in
randomized trials comparing hypothermiawith regular care.
In a systematic review by our group, these trials were
assessed as having a high risk of bias.10 Consequently we
believe that the accrued evidence supporting the clinical use
of hypothermia after adult cardiac arrest resembles that of a
drug following small phase-II trials. This is also reflected by
the level of evidence found in current guidelines in which
TTM is recommended, based on low-quality evidence for
patients with an initial shockable rhythm and based on very
low-quality evidence for patients with an initial non-
shockable rhythm.11,12 Guidelines further recommend
maintaining a constant temperature of between 32°C and
36°C for those patients in whom temperature control is
used, based on the results of the TTM-trial (TTM1) which
showed no difference between a target temperature of 33°C
compared with 36°C.13
In line with the drug trial comparison, there is a need for a
large confirmatory trial on hypothermia for treatment of
comatose cardiac arrest survivors, similar to a phase-III drug
trial. To address this evidence gap we have designed the
TTM2-trial, to compare hypothermia with a control group
targeting normothermia with early treatment of fever.
To ensure that the TTM2 trial is warranted, on 26th
September 2018 we searched for trials assessing the effects
of hypothermia after out-of-hospital cardiac arrest in
PubMed. We found no new randomized trials comparing
hypothermia with normothermia since our prior meta-
analysis.10 Our conclusionwas that the evidence supporting
hypothermia over normothermia is of low quality thus
remains unchanged. A different conclusion was found by an
independent group in a Cochranemeta-analysis 2016,which
judged the overall quality of the included studies to be at a
higher level. However, only three studies, with a total of 383
participants, were included in the assessment of the effects
of hypothermia compared with no hypothermia on risk of
death, and random error was not assessed.14Methods
Trial design
The TTM2-trial protocol was designed according to
SPIRIT guidelines and the trial will be reported according
to the CONSORT guidelines15. It is registered at
clinicaltrial.gov (NCT02908308). The full trial protocol
is available at www.ttm2trial.org.
The TTM2-trial is an international, multicenter,
parallel group, investigator-initiated, randomized, supe-
riority trial in which a target temperature of 33°C after
cardiac arrest will be compared with a target of
normothermia with early treatment of fever
(≥37.8°C). As a pragmatic measure, general intensive
care management will be according to standard
practice at participating hospitals and multiple temper-
ature management devices will be allowed. A pragmat-
ic approach will also be taken to inclusion, by further
minimizing exclusion criteria compared to the TTM1-
trial.16
Rapid cooling in the hypothermia group will be
achieved by means of cold fluids and cooling devices
(intravascular/body-surface/nasal/esophageal). A closed
loop surface or intravascular cooling system will be used
to maintain the target temperature. In the normothermia
arm the aim will be to maintain normothermia using
conservative measures (eg, exposure, lowering of
ambient temperature and cold fluids). For participants
who develop a temperature of 37.8°C (trigger), a device
will be used and set at 37.5°C for the remainder of the
intervention period. At 28 hours after randomization the
participants in the hypothermia group will be rewarmed
over 12 hours. Participants who remain unconscious will
be assessed according to a conservative protocol based
on the European Resuscitation Council (ERC)’s recom-
mendations for neurological prognostication after cardi-
ac arrest. Follow-up and outcome assessment will be
performed at 30 days, 6 and 24 months after cardiac
arrest.
Inclusion criteria
The trial population will be adults (18 years of age or
older) who experience a cardiac arrest of a presumed
cardiac or unknown cause with stable return of
spontaneous circulation (20 minutes with signs of
circulation without the need for chest compressions)
and who are unconscious (FOUR score motor response
b4 and does not obey verbal commands). Participants
should also be eligible for intensive care without
limitations (eg, absence of a ‘do not resuscitate’ order
or a decision not to escalate care) to be included in the
trial. Screening should be performed as soon as
possible, but no later than 180 minutes after return of
spontaneous circulation (ROSC). The inclusion window
will thus be 160 minutes (180 min minus 20 min of
sustained ROSC).
Table I. Trial phases
Time Hypothermia Normothermia
ROSC and 20 minutes of spontaneous
circulation
Sustained ROSC
Sustained ROSC + max 160 minutes Inclusion window: screening and randomization as soon as
possible.
0 h RANDOMIZATION
0 h – 28 h 1. Rapid cooling to ≤33.0°C
(device may be set to 32.0°C to increase speed of cooling)
2. Maintenance at 33.0°C
(device set at 33.0°C)
Device started if temperature ≥ 37.8°C (device set
at 37.5°C)
28 h – 40 h Rewarming (1/3°C per hour)
40 h – 72 h Sedation is discontinued or tapered according to clinical state.
If device used, continued active temperature control in
normothermic range (36.5–37.7°C), unless awake and extubated
96 h Prognostication
All times are in reference to the time of randomization which will be considered time 0. ROSC, Return of spontaneous circulation.
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Exclusion criteria will be pregnancy, known or
suspected intracranial bleeding, an unwitnessed arrest
with an initial rhythm of asystole, and an admission
temperature b30°C. Patients for whom extracorporeal
membrane oxygenation (ECMO) is started prior to ROSC
will also be excluded, as will those who have severe
chronic obstructive pulmonary disorder (COPD) with
home oxygen therapy (Table II).
Randomization
Randomization will be performed by a healthcare
professional in the emergency department, in the
angiography suite or in the intensive care unit via web-
based application using permuted blocks with varying
size, stratified by site. For those participants who are co-
enrolled in the TAME-trial, randomization will also be
stratified according to group allocation in the TAME-trial
(2×2 factorial allocation).
Intervention
The intervention period will commence immediately
after randomization. Participants allocated to hypother-
mia at 33.0°C, will be cooled as rapidly as possible with
available cooling equipment including an intravascular or
surface closed-loop device to 33.0°C. Local protocols
should emphasize speed of cooling. However, we
recognize that cooling speed may vary between centers
as the choice of the main temperature management
device will be at the discretion of the treating physician.
Both surface and intravascular devices will be allowed,
although they must be approved and include feedback-
control. Upon reaching this first temperature goal a
maintenance phase will commence, which will end 28
hours after randomization. During the maintenance
phase the target temperature will be 33.0°C. Themaintenance phase will be followed by rewarming at
1
3
°C/hour for 12 hours (See Table I).
In the normothermia group the participants' tempera-
ture trajectory will be followed, and the aim will be to
keep a temperature below or at 37.5°C. If conservative
and pharmacological measures are insufficient and the
temperature reaches 37.8°C, cooling with a device will
be initiated with the device set at 37.5°C to ensure
normothermia. Participants in whom active temperature
management is initiated will be kept at 37.5°C until 40
hours after randomization. If the participant's body
temperature spontaneously is below 37.5°C there will
be no active warming.
In both groups, active rewarming will only be allowed,
but not mandated, if the initial temperature is between
30.0°C and 32.9°C. In this case active rewarming with a
device may be performed, at the discretion of the treating
physician until the temperature reaches 33.0°C, at which
point active rewarming should cease. Active rewarming
in this range should be considered a safety measure to
avoid arrhythmias associated with a temperature below
32°C.
Measurements of temperature during the intervention
will be performed using a bladder probe. If a bladder
probe is unfeasible or unreliable; esophageal or intravas-
cular temperature probes will be used.
Participants in both groups will be sedated, mechani-
cally ventilated and hemodynamically supported through-
out the intervention period of 40 hours. Short-acting
drugs are recommended for sedation and analgesia and
should be titrated to achieve a Richmond Agitation-
Sedation Scale (RASS) of at least minus 4 (deep sedation).
Shivering will be treated according to a protocol, with
both allocation arms receiving prophylactic acetamino-
phen/paracetamol. This drug may be withheld at the
Table II. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Adult (18 years or older) Pregnancy
Out-of-hospital arrest of cardiac or
unknown cause.
Known or suspected intracranial
bleeding
Stable ROSC (20 minutes without
the need for chest compressions)
E x t r a c o r p o r e a l m emb r a n e
oxygenation required before ROSC
Unconscious (FOUR motor score b4
and does not obey verbal
commands)
Initial body temperature b30°C
Eligible for intensive care without
restrictions
Se ve r e ch ron i c obs t r u c t i v e
pulmonary disorder (COPD) with
home oxygen therapy.
Unwitnessed cardiac arrest with an
initial rhythm of asystole
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contraindication to acetaminophen/paracetamol admin-
istration (eg, hypersensitivity or liver failure). The goal
will be to maintain a score of 0 or 1 on the bedside
shivering assessment scale (BSAS).17
Blinding
The clinical team responsible for the participant
(physicians, nurses and others) and involved with direct
patient care will not be blinded to allocation group due to
the inherent difficulty in blinding the intervention.
Measures will be taken to ensure that the information
about allocation will not disseminate beyond the
immediate group of caregivers responsible for patient
care. A blinded physician will evaluate the patient at 96
hours after randomization and make a statement on
neurological prognosis.
The intensive care physician will not be allowed to
share any information regarding temperature allocation
group. Participants, their legal representatives, and family
will only be informed that the patient has received a
temperature intervention. Health personnel responsible
for outcome assessment at follow-up will be blinded to
the allocation of the intervention. The steering group,
author group, statisticians and the trial coordinating team
will be blinded to group allocation. The two intervention
groups will be coded as “A” and “B”. Two manuscripts
will be written: one assuming that “A” is the experimental
group and “B” is the control group—and one assuming
the opposite. Both manuscripts will be approved by the
author group before the code is broken. Group analyses
of variables that might unblind the randomization (ie,
potassium, lactate, heart rate) will not be allowed before
the manuscripts have been completed.
Prognostication and withdrawal of life-sustaining
therapies
Withdrawal of life-sustaining therapies (WLST) based
on a presumed poor neurological prognosis should not beperformed before prognostication. However, should
further life-sustaining therapies be deemed unethical
due to irreversible organ failure, a medical comorbidity or
other reasons, life-sustaining therapies may be withdrawn
prior to the time point of protocolized prognostication, in
which case the reason will be recorded. WLST for
participants in whom brain death is established will be
defined as death, rather than withdrawal of life-sustaining
therapies.
Prognostication will be performed on all participants
still in the ICU at 96 hours after randomization. The
prognostication will be based on the ERC and
European Society for Intensive Care Medicine recom-
mendations 12,34 and performed at approximately 96 h
after randomization, but may be delayed due to
practical reasons (such as weekend or national
holiday). Efforts will be made to sufficiently delay
prognostication to ensure that any lingering effects of
sedative agents will not affect the assessment.
The physician performing the prognostication will be
a neurologist, intensivist or other specialist experi-
enced in neuroprognostication after cardiac arrest and
who has not been otherwise involved in patient care.
The prognosticator will be blinded for group alloca-
tion, but not for relevant clinical data. Prognostication
and the potential decision to withdraw active life-
sustaining therapies are closely related but will be
considered separate entities.
The result of the prognostication will be categorized as
“YES” or “NO”, based on the answer to the question
“Does this patient fulfil the TTM2-trial criteria for a likely
poor neurological outcome?”. This assessment will be
recorded and communicated to the treating clinician.
Any decision to withdraw active life support will be
made by the treating physicians, together with the
patient's relatives or legal surrogates, as required by
local legislation. In making this decision the treating
physician may use the information from the prognostica-
tion together with all other relevant information about
the patient. The blinded external physician will not make
any recommendation on limitations in care.
TTM2 criteria for a likely poor neurological prognosis
In the TTM2 trial the prognosis is considered likely
poor if criteria A, B and C are all fulfilled.
A. Confounding factors such as severe metabolic
derangement and lingering sedation has been
ruled out.
B. The patient has no response or a stereotypic
extensor response to bilateral central and periph-
eral painful stimulation at ≥96 hours after
randomization.
C. At least two of the below mentioned signs of a poor
prognosis are present:
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reflexes at 96 h after cardiac arrest or later
C.2. A prospectively documented early (within
48 hours). status myoclonus (continuous
and generalized myoclonus persisting for at
least 30 min
C.3. A highly malignant EEG-pattern according to
the TTM2 definition without reactivity to
sound and painful stimulation.18
C.4. CT brain with signs of global ischemic injury,
such as: generalized edema with reduced gray/
white matter differentiation and sulcal efface-
ment or MRI-brain with signs of global, diffuse,
or bilateral multifocal ischemic lesions.
C.5. Serial serum-NSE samples consistently higher
than locally established levels associated with a
poor outcome
C.6. Bilaterally Absent SSEP N20-responses more
than 48 hours after randomization.
Follow-up
At 30 days after randomization, a blinded outcome
assessor will perform the first follow-up. For those
participants who have been discharged, this follow-up
will be performed by telephone. But for some
participants, this will take place face-to-face in
hospital. At 6 months and at 24 months, participants
will be invited to a face-to-face follow-up visit for a
detailed evaluation of neurological function, cognitive
function, quality-of-life, and participation in society,
including return to work.
Outcome measures
The primary outcome measure will be all-cause
mortality. Secondary outcome measures will be: the
proportion of participants with a poor functional
outcome according to the modified Rankin Scale (mRS),
number of days alive and outside hospital, health-related
quality of Life (HRQoL) using EQ-5D-5 L, and survival
assessed as time-to-death. All outcomes (except time-to-
death) will be assessed at 6 months after randomization.
These outcomes follow international recommendations
of the recently published Core Outcome Set for Cardiac
Arrest trials (COSCA).19
The mRS is a hierarchical rating scale consisting of
seven categories (0–6) to reflect overall functional
recovery. There is strong evidence that the mRS has
good psychometric properties and is a valid instru-
ment to assess functional outcome related to neuro-
logical disability.20,21 The mRS has also been used in
a number of cardiac arrest trials to evaluate neuro-
logical outcome.19 Problems with inter-rater reliability
for the mRS have been described, but may be less
problematic if using the dichotomization of good andpoor. Poor functional outcome in TTM2 will be
defined as mRS 4–6. Inter-rater reliability is also
increased if there is a structured approach to scoring,
and training, which will be provided within the trial.
The choice of the mRS as the main neurological
assessment in the trial is based on the recommenda-
tions by COSCA and increased granularity, especially
in the range of no-mild symptoms, compared to the
CPC-scale.22
HRQoL will be assessed by the EQ-5D-5 L,21 a well-
known generic health survey used to assess patient-
reported health. Psychometric properties for the EQ-
5D-5 L have been found superior to the earlier EQ-5D-
3 L.23 EQ-5D-5 L consists of five questions/dimensions
(mobility, self-care, usual activities, pain/discomfort
and anxiety/depression) and a VAS scale of overall
self-reported health. Responsiveness to change has
not yet been described for the EQ-5D-5 L, but the EQ-
5D-3 L demonstrates evidence of responsiveness,
although primarily in situations with large clinical
improvement.
Adverse events
Adverse events, defined as “any untoward medical
occurrence in a clinical trial subject” will not be reported
in this trial. Participants will, because of the circum-
stances of their admission be monitored and treated for a
vast number of untoward medical occurrences, and this is
considered standard care.
The incidence of a number of pre-defined serious
adverse events will be reported (Table III). In addition to
the pre-defined events, investigators will also report any
unexpected serious adverse event.
Statistics
A detailed statistical analysis plan will be submitted for
publication before the last participant is included in the
trial. Our primary conclusions will be based on the results
of the primary outcome. Outcome measures will be
analyzed for all randomized participants in the intention-
to-treat (ITT) analysis, which will be the primary result of
the trial. Per-protocol analyses may be considered if
important deviations from the protocol compromise the
validity of the ITT analysis. Main results will be presented
with adjustment for site (as a random effect) and co-
enrolment in TAME-trial. The primary outcome will be
analyzed as a binary variable (alive versus dead) at 6
months using mixed model logistic regression. Functional
outcome will be evaluated by dichotomizing the modified
Rankin scale (0-3 vs 4-6) and using mixed model logistic
regression. Survival data will be analyzed using Cox
regression.
The secondary outcome HRQoL will be presented as
the difference in EQ5D-5 L VAS-score and this outcome
will be analyzed using mixed model linear regression.
Table III. Definition of specific serious adverse events
Serious adverse event Definition
Pneumonia Pragmatic modification (due to TTM) of the CPIS
score;24 increased or purulent tracheal secretions,
new or progressive radiographic infiltrate and a
decreased P/F-ratio should all be present.
Sepsis and septic
shock
According to the 3rd international consensus
definitions for sepsis and septic shock.25
Bradycardia Requiring pacing
Moderate or severe
bleeding
According to the GUSTO criteria.26
Device related skin
complications
Blistering or skin necrosis in areas covered by
surface device.
Arrhythmia Resulting in hemodynamic compromise (for
example: VF and VT)
TTM, Targeted temperature management; CPIS, Clinical Pulmonary Infection Score; P/
F-ratio, ratio of arterial oxygen partial pressure to fractional inspired oxygen,GUSTO,
Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded
Coronary Arteries, VF, ventricular fibrillation; VT, ventricular tachycardia.
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Elteren test. Time-to-death will be analyzed using Cox
regression. Reporting on secondary outcomes will be
limited to point estimates of treatment effects and
confidence intervals. Pre-defined subgroup analysis will
be performed based on age, sex, presence of bystander
CPR, initial rhythm, time to ROSC, and circulatory state at
admission.
Sample size
Based on the results of the TTM1-trial and informa-
tion in the international cardiac arrest registry,
(INTCAR) we estimate a mortality of approximately
55% in the control group (normothermia group).27
Using an absolute risk reduction of 7.5% as the
anticipated intervention effect of hypothermia, an
acceptable alpha of 5%, and an acceptable beta of
10%, 931 participants are required in each group. The
sample size calculation corresponds to a relative risk
reduction (RRR) of 13.6% and a number needed to treat
(NNT) of 14.6,7 To allow for a possible loss to follow-up
we will recruit 1900 participants; loss to follow up was
minimal in our previous trial.13
Power calculations for the secondary outcomes are
estimated to ensure the validity of including the studied
parameters, but they are not adjusted for multiplicity.
With 931 participants per group, the functional
outcome measure (dichotomized mRS) has a power
of 90% to detect a relative risk of 0.86 based on a poor
outcome (mRS 4–6) in 55% of cases in the control
group. For the secondary outcome survival, we
estimate a power of N90% based on the survival
estimates mentioned above. Health-related quality of
life will be reported for survivors. We estimate a power
of 85% to detect a difference in five points on the VAS-scale, based on a mean value of 70 in the control group
and a standard deviation of 25 points. The secondary
outcome “days alive outside hospital” has an estimated
power of 89%, based on simulations where 8% of
deaths occur outside hospital.
Data monitoring committee and interim analysis
There will be an independent Data Safety Monitoring
Committee (DSMC) arranging an independent statistician
to conduct blinded interim analysis. The DSMC will be
able to request unblinding of data if they find it necessary.
The DSMC will be provided with data on survival and
safety parameters continuously during the conduct of the
trial and can initiate analysis at any time they request. Lan-
DeMets group sequential monitoring boundaries will be
used to adjust thresholds for statistical significance
according to the accrued sample size.28 The DSMC may
stop or pause the trial if:
• Group difference in the primary outcome measure is
found in the interim analysis according to pre-defined
stopping rules.
• Group difference in serious adverse events is found in
the interim analysis.
• Results from other trials show benefit or harm with
one of the allocation arms.
Trial status and timeline
Randomization commenced in November 2017, and
trial sites have been added gradually. We anticipate that
the last six-month follow-up will be performed in 2021.
Results of the primary and secondary outcomes at 6
months will be reported in the initial publication.
Explorative outcomes and results from the 24-month
follow-up will be reported separately.Co-enrolment in the TAME trial
The Targeted Therapeutic Mild Hypercapnia After
Resuscitated Cardiac Arrest: A Phase III Multi-Centre
Randomized Cont ro l l ed Tr i a l (TAME t r i a l )
(NCT03114033) aims to determine whether targeted
therapeutic mild hypercapnia improves neurological
outcome at 6 months compared to standard care and
targeted normocapnia. Co-enrolment in this trial will be
allowed, and encouraged for sites participating in the
TTM2-trial.29 However, the option to participate in only
the TTM2-trial will be retained for sites that are not
willing, or able to co-enroll. We consider co-enrolment in
TTM2 and TAME as an effective utilization of research
resources. A difficulty with co-enrolment is the potential
for an interaction between the interventions. However,
data analysis from the TTM1-trial shows no interaction
between temperature and pCO2 with regard to major
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studying the combination of hypothermia and hypercap-
nia, we acknowledge the possibility that a biological
interaction might be identified. As randomization will be
stratified to achieve a two-by-two factorial design, any
differences in primary or secondary outcomes will
become evident to the data safety monitoring committee
which will monitor both trials. An assessment of the
interaction term will also be performed in the final
analyses.
Data from the Australian New Zealand Intensive Care
Society Adult Patient Database suggest a large variation of
carbondioxide tension among survivors of cardiac arrest.31
We therefore do not anticipate a significant effect on
external validity, although a possible consequence of co-
enrolment might be a lower incidence of hypocapnia. As
temperature measurements are not affected by the TAME
intervention and stratificationwill be performed,wedonot
believe that internal validity will be compromised.
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The evidence for hypothermia in a broad context is
conflicting. Clinical trials in various areas of brain damage
indicate both benefit and harm.32,33 Theoretical rationale
exists and currently hypothermia is the only clinical
strategy aiming for neuroprotection for cardiac arrest
victims. Specifically, in adults with cardiac arrest with
shockable rhythms low quality evidence indicate benefit
of 33°C and moderate quality evidence indicate no
difference between 33°C and 36°C. The recent TTM1-
trial has had a significant influence on the new ILCOR,
AHA and ERC statements and guidelines for 2015,11,34
which have adopted the view that different temperature
targets provide similar clinical results. The recommended
temperature range has also been changed to include
36°C. Most importantly, however, is that the overall
evidence level for temperature management after out-of-
hospital cardiac arrest has been changed to low to very-
low, in line with our conclusion from the meta-analyses
performed in 2010.10
Internationally, many hospitals and regions have
already changed strategy in favor of TTM at 36°C,
reasoning that a less invasive and easier administratedtemperature strategy yielding the same clinical results is
preferable. Some hospitals however remain at 33°C based
on earlier evidence while others, motivated by a lack of
robust evidence, do not use temperature management at
all.35-37 Recent studies have shown a trend towards an
increased mortality and an increased incidence of fever
since 2014, when many hospitals changed their target
temperature to 36°C. No causal links have been
identified, but this has increased the uncertainty about
optimal temperature targets.38,39
Based on the above, and the knowledge gaps indicated
in international guidelines, it is reasonable to assess
whether rapidly administered hypothermia to a low
target level is beneficial, and to define subgroups, where
the intervention effect can be studied. At the same time, it
is important to clarify if early treatment of fever (easier,
less costly and less invasive than the 36°C-arm in the
TTM1-trial) is sufficient to achieve a good functional
outcome.Rationale for early treatment of fever
Fever has been proposed as a risk factor for death after
Cardiac arrest (CA) although it still remains an open
question if it is a causative risk factor. Zeiner and
colleagues showed an increase in the odds of a poor
neurological outcome for each degree in peak temper-
ature higher than 37°C, within 48 h of arrest.40
However, a body temperature above 37°C can occur
due to individual or diurnal variation. When tempera-
ture is measured in a large population it appears that
37°C has no special significance to human thermome-
try.41,42 It therefore seems reasonable to apply a less
strict definition of fever than N37.0°C. At the other end
of the spectrum, it could be argued that it would be
problematic to allow temperatures up to 38.3°C (A level
usually employed in the definition of fever of unknown
origin) even if this is based on no or very low quality
evidence.43
This trial will employ normothermia-targeted tempera-
ture management in the control arm, with 37.8°C as a
trigger for active temperature management with a
feedback device. Although any temperature cut-off is
arbitrary, the choice of this value is motivated by the
following.
• Diagrammatic data from the HACA-trial6 suggests a
median temperature between 37.5°C and 37.8°C
among participants in the control arm of the trial. If a
similar distribution is assumed in the current trial a
substantial number of participants will not require a
device, thus making temperature management consid-
erably less labor and resource intense.
• 37.7°C has been proposed as the upper limit of normal
body temperature in healthy adults.41,44 Employing
active fever control for any patient who exceeds this
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proach to fever control.
• Temperature fluctuations are unavoidable. In the
TTM1-trial, the measured temperature among partici-
pants allocated to TTM at 36°C had a standard
deviation of approximately 0.5°C. Assuming a similar
variation around 37.5°C (for patients in whom active
temperature management is used), few patients would
become unequivocally febrile with temperatures
above 38.3°C.)
Strengths and limitations
Strengths of the TTM2-trial include a large sample size
with a reasonable absolute risk reduction, when com-
pared to other interventions used in the ICU. An
international collaboration, including different health-
care settings and broad inclusion criteria vouch for a
representative group of participants. A further strength is
the blinding of outcome assessors, prognosticators, the
steering group, author group, statisticians, and the trial
coordinating team – and our choice of outcomes that are
both patient-centered and clinically important. We
deliberately designed the assessment of neurological
prognosis and the approach to withdrawal of care to be
more conservative compared to current international
guidelines which we also consider a major strength.
The primary limitation of our trial is the choice of
control intervention. There is a no clear evidence of
causality between fever and poor neurological outcomes,
but observational data have shown an association.40
While a total laissez-faire attitude to temperature in the
control group would be a benefit from a methodological
point of view, we have chosen to include an intervention
of fever-control. This decision is based on earlier
observational data and uncertainty about how control
group temperature management was conducted in prior
trials.6,7 From a practical stand point fever-control is also
an intervention acceptable to clinicians who are strong
proponents of hypothermia, which makes global recruit-
ment feasible. Active fever prevention was studied in a
recent trial on brain injury due to trauma,45 but fever-
control is largely unstudied, and its clinical effects are
uncertain which needs to be taken into consideration
when the results of the trial are to be interpreted.
Another important limitation of the trial is the
compromise between the study of effectiveness of
hypothermia and a pragmatic design. The true effect of
hypothermia might be underestimated as the control
group includes a temperature intervention, at the same
time the pragmatic aspect of the trial is limited by
mandated sedation in both allocation groups. Another
drawback of a pragmatic design is a potential heteroge-
neous intervention effect, depending on the mode of
cooling, and hence different speeds of cooling.Conclusion
A large confirmatory trial is needed to investigate the
effectiveness of hypothermia after out-of-hospital cardiac
arrest. To study the use of a temperature management
strategy that does not mandate a device in all cases is also
necessary. We believe that a pragmatic trial with a clear
separation in temperature between groups is the best
option. Considering the international collaboration and
broad inclusion criteria we expect the results of the
TTM2-trial to be broadly applicable to the care of
survivors of cardiac arrest treated in the intensive care
setting.Disclosure
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